Therapeutic efficacy of modified decoction for dissipating stasis in the epiglottis in the treatment of phlegm-stasis intermingling type chronic tonsillitis
10.3760/cma.j.cn341190-20240319-00279
- VernacularTitle:会厌逐瘀汤加减治疗痰瘀互结型慢性扁桃体炎疗效观察
- Author:
Zhihua GE
1
;
Fei LI
;
Fangzi BIAN
Author Information
1. 西安市中医医院耳鼻喉科，西安 710000
- Keywords:
Tonsillitis;
Medicine, Chinese traditional;
Signs and symptoms;
Leukocyte count;
T-lymphocyte subsets;
C-reactive protein;
Interleukin-3;
Amoxicillin
- From:
Chinese Journal of Primary Medicine and Pharmacy
2024;31(11):1655-1660
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the therapeutic efficacy of modified decoction for dissipating stasis in the epiglottis in the treatment of phlegm-stasis intermingling type chronic tonsillitis and its effects on patients' traditional Chinese medicine (TCM) symptom scores, white blood cell count (WBC), and serum interleukin-3 (IL-3) levels.Methods:A total of 120 patients with phlegm-stasis intermingling type chronic tonsillitis who received treatment at Xi'an Hospital of Traditional Chinese Medicine from January 2022 to October 2023 were selected for this randomized controlled study. The patients were randomly divided into two groups of 60 each using a random number table method. The control group received amoxicillin capsules combined with open-throat sword spray, while the observation group was treated with modified decoction for dissipating stasis in the epiglottis. All patients were treated for 14 days. Clinical efficacy was evaluated in each group. TCM symptom and sign scores, serum T-lymphocyte subgroups, WBC, high-sensitivity C-reactive protein (hs-CRP), and IL-3 levels were compared between the two groups before and after treatment.Results:The total response rate in the observation group was 93.33% (56/60), which was significantly higher than that in the control group [80.00% (48/60), χ2 = 4.62, P < 0.05]. After treatment, the scores for symptoms including dry and astringent pharynx, prolonged soreness, itchy pharynx, cough with white sputum, chest and epigastric congestion, and poor appetite were significantly lower in both groups compared with their baseline scores (all P < 0.001). After treatment, all symptom scores in the observation group were significantly lower than those in the control group ( t = 8.08, 18.01, 13.36, 8.75, 8.57, 9.17, all P < 0.001). The WBC, hs-CRP, and IL-3 levels in the observation group were (8.23 ± 1.44) × 10?/L, (5.62 ± 1.27) mg/L, and (81.36 ± 8.87) ng/L, respectively. These values were significantly lower than those in the control group [(10.05 ± 1.91) × 10?/L, (8.23 ± 1.78) mg/L, (97.43 ± 10.22) ng/L, t = 5.89, 0.95, 9.20, all P < 0.001]. After treatment, the ratios of CD 4+/CD 8+, NK lymphocytes, and CD 4+ levels in each group were significantly higher than their pre-treatment values (all P < 0.001). After treatment, these values in the observation group were significantly higher than those in the control group ( t = 2.30, 6.31, 5.97, 6.60, all P < 0.05). The difference in the incidence of adverse events between the two groups was not statistically significant ( P > 0.05). Conclusion:The treatment of phlegm-stasis intermingling type chronic tonsillitis with a modified decoction for dissipating stasis in the epiglottis can reduce WBC, and hs-CRP and IL-3 levels. It also improves T-lymphocyte subpopulations, alleviates symptoms, and enhances therapeutic efficacy.
